A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

May 24, 2024

Study Completion Date

May 24, 2024

Conditions
Alzheimer Disease
Interventions
DRUG

E2814

E2814 intravenous infusion.

Trial Locations (3)

46202

Indiana University School of Medicine, Health Partners, Adult Neurology Clinic, Indianapolis

92037

UC San Diego Altman Clinical and Translational Research Insititute Clinic, La Jolla

WC1N 3BG

National Hospital for Neurology and Neurosurgery (NHNN) University College London(UCL) Hospitals NHS Foundation Trust, London

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY